Literature DB >> 8773813

A controlled study of education about drug treatment in schizophrenia.

R Macpherson1, B Jerrom, A Hughes.   

Abstract

BACKGROUND: Various problems are associated with schizophrenia which may theoretically lead to impaired educability about treatment.
METHOD: The Understanding of Medication Questionnaire, designed to measure knowledge about treatment in schizophrenia, is described and presented. An educational programme based on a specially designed information booklet was developed. Sixty-four patients with DSM-III-R diagnosis schizophrenia were randomly allocated to groups receiving none (control), one session or three sessions of education.
RESULTS: Pre-intervention low levels of knowledge about illness and treatment increased significantly immediately after a standard education session. Three education sessions led to significantly greater knowledge gain than one session. There was no significant change in the control group. Only the PANSS negative syndrome score independently and consistently explained a significant proportion of the education effect. The influence on educability of attitudes to education, impaired insight, cognitive impairment and other variables were considered. Three sessions of education led to significantly increased insight, but no change in compliance.
CONCLUSIONS: Techniques appropriate for educating schizophrenic patients were discussed, and the value of involving patients in education emphasised. A series of patient education sessions is needed to consolidate learning, rather than a single informing process. The strong association between impaired learning and more severe negative schizophrenic syndrome emphasises the need for responsible prescribing of antipsychotic treatment in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8773813     DOI: 10.1192/bjp.168.6.709

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  16 in total

1.  Family interventions for mental disorders: efficacy and effectiveness.

Authors:  Ian R H Falloon
Journal:  World Psychiatry       Date:  2003-02       Impact factor: 49.548

Review 2.  Lack of insight in schizophrenia: impact on treatment adherence.

Authors:  Peter F Buckley; Donna A Wirshing; Prameet Bhushan; Joseph M Pierre; Seth A Resnick; William C Wirshing
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

3.  Management of schizophrenia : an update.

Authors:  P Kulhara
Journal:  Indian J Psychiatry       Date:  1998-04       Impact factor: 1.759

4.  A research induction group for clients entering a mental health research project: a replication study.

Authors:  R R Bebout; D R Becker; R E Drake
Journal:  Community Ment Health J       Date:  1998-06

5.  Potential negative impact of informing patients about medication side effects: a systematic review.

Authors:  Jimmy Jose; Lamia AlHajri
Journal:  Int J Clin Pharm       Date:  2018-08-23

Review 6.  Psychoeducation for schizophrenia.

Authors:  Jun Xia; Lars Bertil Merinder; Madhvi R Belgamwar
Journal:  Cochrane Database Syst Rev       Date:  2011-06-15

Review 7.  The impact of informing psychiatric patients about their medication: a systematic review.

Authors:  Franciska A M Desplenter; Steven Simoens; Gert Laekeman
Journal:  Pharm World Sci       Date:  2007-01-10

8.  Desire for information about drugs: a survey of the need for information in psychiatric in-patients.

Authors:  Lieven Zwaenepoel; Rita Bilo; Willy De Boever; Marc De Vos; Johan Reyntens; Vera Hoorens; Walter Sermeus; Gert Laekeman
Journal:  Pharm World Sci       Date:  2005-02

9.  Randomised trial of personalised computer based information for patients with schizophrenia.

Authors:  R B Jones; J M Atkinson; D A Coia; L Paterson; A R Morton; K McKenna; N Craig; J Morrison; W H Gilmour
Journal:  BMJ       Date:  2001-04-07

Review 10.  Defining and assessing adherence to oral antipsychotics: a review of the literature.

Authors:  Dawn I Velligan; Yui-Wing Francis Lam; David C Glahn; Jennifer A Barrett; Natalie J Maples; Larry Ereshefsky; Alexander L Miller
Journal:  Schizophr Bull       Date:  2006-05-17       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.